SAB Biotherapeutics, Inc. SABS
Set alert
3.35 USD +0.12 +3.72%
At close · Oct 30
3.35 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
3.11 Day range 3.37
2.49 52-week range 4.59
- YTD
- -10.43%
- 1 year
- +11.30%
- Open
- 3.20
- Prev close
- 3.23
- Mkt cap
- 304.80M
- Vol
- 741.05K
- Avg vol
- 536.84K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.11
- High
- 3.37
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
2Y chart
Events in this range
- Nov 6, 2024Earnings: -1.12; estimate -1.07; surprise -4.67%
- Nov 7, 2024Rating: Chardan Capital · Buy → Buy
Signals (120)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 26, 2026 | 8 months ago |
| SMA: Bearish | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| RSI: Overbought | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 26, 2025 | 11 months ago |
| RSI: Overbought | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| RSI: Overbought | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 13, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| RSI: Overbought | Nov 12, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 10, 2025 | 11 months ago |
| RSI: Overbought | Oct 31, 2025 | 1 year ago |
| SMA: Bullish | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| SMA: Bearish | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| SMA: Bullish | Sep 17, 2025 | 1 year ago |
| SMA: Bullish | Sep 17, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 17, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 3, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| RSI: Overbought | Jul 8, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 2, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Jan 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 2, 2025 | 1 year ago |
| RSI: Overbought | Dec 9, 2024 | 1 year ago |
Key statistics
- Market cap
- 39.50M
- Enterprise value
- 17.04M
- Trailing P/E
- 0.00
- Forward P/E
- -1.56
- PEG ratio
- 0.00
- Price / sales
- 26.11
- Price / book
- 1.07
- EPS (TTM)
- -6.30
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.51M
- Revenue growth
- 0.00%
- Free cash flow
- -26.31M
- Total cash
- 30.40M
- Total debt
- 4.52M
- Return on equity
- -174.73%
- Shares outstanding
- 9.23M
- Short % of float
- 1.41%
- 50-day average
- 3.29
- 200-day average
- 3.35
Analyst view
Consensus: none
Price target (mean) 12.40 +270.1% upside
Now 3.35
- Target (low)
- 6.00
- Target (mean)
- 12.40
- Target (high)
- 25.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.21.
Financials — quick view
SABS Revenue — quarterly 0
SABS Net income — quarterly -22.49M
SABS EPS — quarterly -0.28
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.07 | -1.12 | -0.05 | -4.67% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | -0.79 | +0.34 | +30.09% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | -0.54 | +0.44 | +44.90% |
| Apr 1, 2024 | Dec 1, 2023 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 9, 2024 | Craig-Hallum | init | — | Buy |
| Sep 12, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Sep 9, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 28, 2024 | Oppenheimer | init | — | Outperform |
| Aug 12, 2024 | Chardan Capital | main | Buy | Buy |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sabbiotherapeutics.com
News
- SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
- SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
- SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
- FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
- SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
- SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
- SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
- SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
- SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- SAB BIO to Participate in Upcoming Investor Conferences
Your note
Sign in to keep a note on SABS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELLIAS HELEN K | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| KING MICHAEL | Chief Financial Officer | Purchase | Nov 29, 2023 | 5,000 |
| KROPOTOVA ALEXANDRA | Officer | Stock Award(Grant) | Mar 13, 2023 | 275,000 |
| MOIN ANDREW D. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| REICH SAMUEL J. | Officer and Director | Purchase | Nov 28, 2023 | 766,699 |
| SESSA CAPITAL MASTER, L.P. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.94% | 917,826 | 3.93M | Sep 29, 2024 |
| RTW Investments LP | 6.88% | 635,276 | 2.72M | Sep 29, 2024 |
| Marshall Wace LLP | 4.98% | 459,168 | 1.97M | Sep 29, 2024 |
| Sessa Capital IM, L.P. | 4.97% | 458,457 | 1.96M | Sep 29, 2024 |
| Vanguard Group Inc | 2.99% | 276,336 | 1.18M | Sep 29, 2024 |
| HB Wealth Management, LLC | 1.18% | 108,600 | 464.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 232,567 | 995.39K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.46% | 42,636 | 182.48K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 41,315 | 176.83K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 14,370 | 61.50K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,940 | 55.38K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 9,834 | 42.09K | Oct 30, 2024 |